| Title |
The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders
|
|---|---|
| Published in |
BioDrugs, June 2013
|
| DOI | 10.1007/s40259-013-0040-7 |
| Pubmed ID | |
| Authors |
Yasuko Furumoto, Massimo Gadina |
| Abstract |
Altered production of cytokines can result in pathologies ranging from autoimmune diseases to malignancies. The Janus kinase family is a small group of receptor-associated signaling molecules that is essential to the signal cascade originating from type I and type II cytokine receptors. Inhibition of tyrosine kinase enzymatic activity using small molecules has recently become a powerful tool for treatment of several malignancies. Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clinical use and others are currently in the final stage of development. Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development. |
Mendeley readers
The data shown below were compiled from readership statistics for 139 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 139 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 26 | 19% |
| Researcher | 24 | 17% |
| Student > Ph. D. Student | 17 | 12% |
| Student > Master | 11 | 8% |
| Student > Doctoral Student | 7 | 5% |
| Other | 22 | 16% |
| Unknown | 32 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 20% |
| Biochemistry, Genetics and Molecular Biology | 22 | 16% |
| Agricultural and Biological Sciences | 16 | 12% |
| Immunology and Microbiology | 9 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Other | 21 | 15% |
| Unknown | 37 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 August 2022.
All research outputs
#1,128,118
of 24,569,575 outputs
Outputs from BioDrugs
#14
of 710 outputs
Outputs of similar age
#9,044
of 201,836 outputs
Outputs of similar age from BioDrugs
#2
of 13 outputs
Altmetric has tracked 24,569,575 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 710 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 201,836 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.